Drug Type Prophylactic vaccine, self-replicating RNA |
Synonyms- |
Mechanism MERS-CoV nucleoprotein inhibitors, SARS-CoV-2 N protein inhibitors(SARS-CoV-2 N protein inhibitors), T-cell surface glycoprotein CD5 inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Preclinical | US | Elixirgen Therapeutics, Inc.Startup | 21 Apr 2023 |
COVID-19 | Preclinical | IL | 21 Apr 2023 |